Baxter progresses with planned kidney care spinoff, expects biopharma solutions sale this quarter

The company expects hospital spending to increase in the second half of the year amid rising procedure volumes and a stabilizing supply chain. 

By Elise Reuter • July 27, 2023

Teleflex to expand urology portfolio with $600M acquisition

The company reached an agreement to buy Palette Life Sciences, as it looks to grow through acquisitions.

By Elise Reuter • July 26, 2023

Big Health buys Limbix to add adolescent depression app to digital therapeutic portfolio

The phone-based treatment, SparkRx, uses self-guided, cognitive behavioral therapy to teach skills such as mood tracking.

By Nick Paul Taylor • July 18, 2023

Illumina hit by EU with maximum €432M fine for Grail acquisition

The European Commission called Illumina’s closing of the deal without its approval an “unprecedented” move that undermines its system for regulating the competitive landscape.

By Susan Kelly • July 12, 2023

Coloplast to pay $1.2B upfront to buy fish skin wound care business Kerecis

Kerecis’ fish skin biologic, which aids tissue regeneration, helped drive the company’s sales to $74.5 million last year.

By Nick Paul Taylor • July 10, 2023

ResMed buys Somnoware to expand sleep management software portfolio

The maker of sleep and respiratory care devices said it plans to retain all of Somnoware’s staff and maintain its open platform for patient testing and treatment.

By Nick Paul Taylor • July 7, 2023

Bausch + Lomb bulks up OTC business with J&J deal

The eye care company has become an active acquirer under new CEO Brent Saunders, buying an eye drop product line one week after purchasing several medicines from Novartis.

By Ned Pagliarulo • July 6, 2023

Thermo Fisher to buy real-world evidence company CorEvitas for $913M

The acquisition is expected to complement Thermo Fisher’s clinical research business and become “immediately accretive” to its adjusted earnings per share.

By Elise Reuter • July 6, 2023

FTC proposes updates to merger review that could slow healthcare dealmaking

A new rule proposed by antitrust regulators would ask companies to provide additional information about planned mergers to help the Federal Trade Commission keep pace with increased deal volume and complexity.

By Emily Olsen • June 28, 2023

Restor3d inks Conformis buyout, adding hip and knee implants to portfolio

Restor3d, which makes 3D-printed devices for spine, ankle and upper extremity procedures, is buying Conformis at a 96% premium. 

By Nick Paul Taylor • June 27, 2023

BD plans $540M sale of surgical instrumentation platform to Steris

The divestiture is part of BD’s strategy to simplify its portfolio and focus on higher-growth markets.

By Peter Green • Updated June 20, 2023

Glass Lewis, joining ISS, supports activist’s candidates for Masimo board

Saying it has “rarely” seen a circumstance where the “need for direct representation of a large shareholder in the boardroom was so apparent,” the proxy advisory firm backed Politan Capital’s bid for two board seats.

By Susan Kelly • June 16, 2023

As Illumina’s deSouza departs, will Grail go next?

The CEO’s resignation could signal a change of direction, as anti-trust regulators order Illumina to divest the liquid biopsy unit.

By Susan Kelly • June 12, 2023

Merit Medical buys two dialysis catheter lines for $132.5M combined

The acquisitions are expected to boost the Utah-based device maker’s annual revenue by about $30 million.

By Susan Kelly • June 9, 2023

SunMed agrees to $110M takeover of Avanos’ respiratory health unit, continuing M&A spree

Avanos, whose competitors include Stryker and Medline Industries, is selling the unit to narrow its focus on areas where it can succeed.

By Nick Paul Taylor • June 9, 2023

Novo Nordisk says in talks to acquire French device-maker Biocorp for $165M

The offer per share is about 20% more than Biocorp’s closing stock price on June 2. The two companies plan to focus on drug delivery solutions for chronic diseases, such as diabetes.

By Elise Reuter • Updated June 6, 2023

Getinge will acquire High Purity for as much as $370M to bolster biopharma business

The acquisition is aimed at strengthening Getinge’s position in the fast-growing area of custom single-use solutions for bioprocessing applications.

By Peter Green • May 31, 2023

Titan licenses robotic surgery intellectual property to Intuitive after failing to find buyer

After failing to bring its surgical robot to market and getting kicked off the Nasdaq, Titan is now marketing its intellectual property.

By Nick Paul Taylor • May 30, 2023

Illumina accused of ‘playing delay tactics’ to push back EU decision on divesting Grail: Financial Times

Delaying the decision to divest Grail could let Illumina sell the liquid biopsy business when the market is more favorable.

By Nick Paul Taylor • May 30, 2023

Boston Scientific cancels $230M stent deal after regulators erect barriers to acquisition

The Federal Trade Commission said Boston Scientific took the action in response to investigations by its staff and overseas enforcement partners.

By Nick Paul Taylor • May 26, 2023

Illumina chair loses to Icahn pick as proxy battle ends

The decision to replace board Chair John Thompson could change the company’s course as it decides whether to divest liquid biopsy company Grail.

By Elise Reuter • Updated May 25, 2023

Medtronic posts profit, sales growth in Q4, agrees to buy Korean diabetes patch maker

The company is “confident in delivering durable revenue growth in the year ahead” amid continued improvements in procedure volumes.

By Peter Green • May 25, 2023

Medtronic agrees to buy Korean insulin patch pump maker for $738m to boost diabetes business

The tubeless, disposable insulin patch made by EOFlow will be integrated into Medtronic’s MiniMed 780G system.

By Elise Reuter • May 25, 2023

A Boston Scientific purchase of Shockwave could be transformative — but at what price?

Boston Scientific has used “tuck-in” acquisitions to boost growth in the past. Some analysts say it should stay the course amid a report the company may make a bid.

By Susan Kelly • May 19, 2023

Icahn bolstered by another proxy advisor in battle with Illumina

The DNA-sequencing company defended its board chair, John Thompson, and drew attention to a new disclosure that Icahn’s firm is being investigated by the U.S. attorney for the Southern District of New York.

By Susan Kelly • Updated May 15, 2023